The raw sequence data used in this study are available from the European Nucleotide Archive (<https://www.ebi.ac.uk/ena>) under accession number PRJEB22153.

Introduction {#sec001}
============

Pulmonary infection with non-tuberculous mycobacteria (NTM) is a challenging disease which is becoming increasingly prevalent. It is associated with a high mortality, and treatment is prolonged, expensive and frequently poorly tolerated \[[@pone.0208018.ref001],[@pone.0208018.ref002]\]. The diagnosis of NTM infection relies upon the isolation of NTM in culture which is challenging due to the overgrowth of other co-pathogens, such as *Pseudomonas*, contamination from environmental mycobacteria and failure to grow due to fastidious requirements, as well as the time and labour involved.

Molecular techniques utilising nucleotide amplification have been used directly on clinical samples in TB infection and have become established in clinical practice \[[@pone.0208018.ref003]\]. Their use in NTM disease, however, is currently confined to the identification of species previously cultured from clinical samples. As well as overcoming the limitations of culture based techniques, the sequencing of mycobacteria directly from a sample has the potential to capture the diversity of mycobacterial species present including rare and as yet unidentified species. This may be valuable, as the isolation of multiple species is not uncommon and may pose a therapeutic challenge \[[@pone.0208018.ref004],[@pone.0208018.ref005]\]. Molecular techniques have been successfully employed in both environmental \[[@pone.0208018.ref006]--[@pone.0208018.ref008]\] and more recently in human samples \[[@pone.0208018.ref009]\].

The aim of this study was to employ next generation sequencing of the *hsp65* gene to characterise mycobacterial communities in the lung directly from sputum samples.

Materials and methods {#sec002}
=====================

Written consent was gained from all participants and the study was approved by the London - Chelsea Research Ethics Committee (reference 12/LO/1034). Subjects were recruited from the outpatient department of the Royal Brompton Hospital between September 2012 and November 2013. Cases were enrolled if they met ATS/IDSA 2007 criteria \[[@pone.0208018.ref010]\] and had non-cystic fibrosis bronchiectasis, chronic obstructive pulmonary disease (COPD) or no underlying lung disease prior to their diagnosis of NTM disease. Controls had non-cystic fibrosis bronchiectasis or COPD with no clinical or radiological evidence of NTM infection, previous negative sputum mycobacterial cultures and a negative sputum mycobacterial culture on enrolment. Exclusion criteria were: pregnancy, immunosuppression (other than oral corticosteroids), and current malignancy or tuberculosis.

Participants underwent clinical assessment and pulmonary function testing. If not performed within the previous six months high resolution computed tomography (HRCT) was performed. Spontaneously expectorated sputum was stored at -80 degrees Celsius for DNA extraction as well as undergoing phenol auramine microscopy and culture for bacteria, mycobacteria and fungi.

Barcoded primers were designed for use with the MiSeq benchtop sequencer (Illumina, San Diego, CA, USA) as previously described \[[@pone.0208018.ref011]\] using the TB11/TB12 primer pair, which amplify a 401bp region of the mycobacterial *hsp65* gene \[[@pone.0208018.ref012]\]. This target was chosen as the amplicon length is suitable for the MiSeq platform, and enables clear differentiation between *M*. *abscessus* and *M*. *chelonae* \[[@pone.0208018.ref013]\] as well as differentiation between *M*. *abscessus* spp. *abscessus* and ssp. *bolletii/massiliense* which are identical by partial sequencing of the 16S rRNA gene \[[@pone.0208018.ref014]--[@pone.0208018.ref016]\].

As a positive control, a mock community was created consisting of *hsp65* amplicons from 16 NTM typestrains cloned, sequenced and pooled in equal abundance. A reference database was created consisting of all mycobacterial *hsp65* sequences present in the National Center for Biotechnology Information (NCBI) GenBank (<http://www.ncbi.nlm.nih.gov/nuccore/>) in addition to the sequences of the NTM typestrains of the mock community and non-mycobacterial sequences which also may be amplified by the TB11/TB12 primer pair, identified using NCBI primer-BLAST (<https://www.ncbi.nlm.nih.gov/tools/primer-blast/>).

For each patient a 300μl aliquot of stored sputum underwent bead-beating and DNA was extracted using hexadecyltrimethylammonium bromide and phenol: chloroform:isoamylalcohol (see supporting information for further information). As a control, molecular-grade water was collected in the same receptacles as used for sputum and subjected to the same storage and DNA extraction protocol. Barcoded *hsp65* sequences were amplified from each DNA sample in quadruplicate and libraries prepared and sequenced using the MiSeq benchtop sequencer and MiSeq v3 600 cycle reagents (Illumina).

Sequence processing was performed using the QIIME pipeline 1.8.0 \[[@pone.0208018.ref017]\] applying a 99% similarity for Operational taxonomic unit (OTU) picking. The resulting data was imported into the R environment version 3.1.2 \[[@pone.0208018.ref018]\] where all downstream analysis was performed. The relative abundance of taxa between groups were compared using the Wilcoxon rank sum test using the Benjamini-Hochberg correction for multiple testing. Diversity metrics were calculated using the phyloseq and vegan packages \[[@pone.0208018.ref019],[@pone.0208018.ref020]\] and compared between groups using the t-test and correlated with clinical variables using Pearson correlation. Differences in community structure were tested using permuted analysis of variance (PERMANOVA) in the vegan package. A *P* value of \< 0.05 was considered significant.

Full details of the *hsp65* database and mock community creation, DNA extraction, library preparation, sequencing and the processing of sequence data can be found in the supporting information. Sequence data are available from the European Nucleotide Archive under accession number PRJEB22153.

Results {#sec003}
=======

Sputum was collected for DNA extraction from 56 eligible subjects. A total of 4.84 million joined sequences were obtained, leading to 4.16 million sequences available for analysis following processing and quality control (for more detail see the supporting information). Samples with a low depth of sequencing (under 5,000 sequences) were removed (N = 14) leaving 42 subjects for analysis with a median depth of sequencing of 80,960 sequences per sample. The clinical characteristics of the final study population are shown in [Table 1](#pone.0208018.t001){ref-type="table"}. All controls were smear and culture negative and had provided at least one prior negative mycobacterial culture (median 4 samples, range 1 to 15).

10.1371/journal.pone.0208018.t001

###### Clinical characteristics of the study population.

![](pone.0208018.t001){#pone.0208018.t001g}

  ------------------------------------------------------------------
                                   Cases\           Controls\
                                   N = 31           N = 11
  -------------------------------- ---------------- ----------------
  **Age (years)**                  65.77 (±11.32)   65.58 (±4.78)

  **Male sex**                     12 (38.7%)       6 (54.5%)

  **Ex- or current smoker**        15 (48.4%)       6 (54.5%)

  **Underlying diagnosis**                          

      COPD                         5 (16.1%)        0

      Bronchiectasis               23 (74.2%)       11 (100%)

      No underlying lung disease   3 (9.7%)         0

  **FEV1% predicted**              52.85 (±29.30)   79.19 (±16.67)

  **FVC % predicted**              89.96 (±32.01)   92.73 (±15.29)

  **Prophylactic antibiotics**     7 (22.6%)        5 (45.5%)

  **Oral steroid**                 1 (3.2%)         2 (18.2%)

  **NTM treatment**                7 (22.6%)        \-

  **NTM species**                                   

      *M*. *abscessus*             4 (12.9%)        \-

      *M*. *avium* complex (MAC)   18 (58.1%)       \-

      *M*. *fortuitum*             1 (3.2%)         \-

      *M*. *kansasii*              5 (16.1%)        \-

      *M*. *malmoense*             1 (3.2%)         \-

      *M*. *simiae*                1 (3.2%)         \-

      *M*. *xenopi*                1 (3.2%)         \-
  ------------------------------------------------------------------

Continuous variables are expressed as mean +/- standard deviation, categorical variables as count and percentage. NTM species refers to the species isolated in culture leading to the original diagnosis of pulmonary NTM disease.

All species within the mock community were detected. The median difference between the observed proportional abundance of each species and the expected proportion was 2.7% (range 0.2% to 5.5%) with *M*. *xenopi* and *M*. *tuberculosis* complex being the most overrepresented and *M*. *abscessus subsp*. *abscessus* and *M*. *peregrinum* being the most underrepresented ([S2 Fig](#pone.0208018.s007){ref-type="supplementary-material"}). There was no evidence of contamination in the negative extraction controls or the negative PCR control.

Genus level {#sec004}
-----------

Mycobacterial sequences were detected in all samples, although only 6.23% of all sequences were from mycobacteria and the median proportion of mycobacterial sequences in each sample was 0.15% ([S3 Table](#pone.0208018.s008){ref-type="supplementary-material"} and [S4 Fig](#pone.0208018.s009){ref-type="supplementary-material"}). The most abundant genus was Actinomyces, accounting for 51.5% of all sequences. Samples tended to be dominated by one genus and in 38 samples one genus represented over 50% of all sequences. In two subjects Mycobacterium was the most abundant genus; both were culture positive for *Mycobaterium avium* complex (MAC) and *M*. *abscessus* respectively. There was no significant difference in the median relative abundance of mycobacteria in cases compared with controls (0.19% vs 0.02%, *P* = 0.65). There was no significant correlation between mycobacterial abundance and *hsp65* amplicon concentration (Spearman rho -0.18 *P* = 0.255, see [S3 Fig](#pone.0208018.s008){ref-type="supplementary-material"} in the supporting information).

Species level {#sec005}
-------------

All sequences from the genus Mycobacterium (N = 258,421) were selected for further analysis. The most common species was *M*. *avium*, followed by *M*. *abscessus* subsp. *bolletii* and *M*. *simiae* ([Table 2](#pone.0208018.t002){ref-type="table"}). In 32 samples the most abundant species constituted over 50% of all mycobacterial sequences. More than one species was identified in 38 (90.5%) of samples. The median number of species present was 5.5 (range 1 to 19). Details of sequencing for each subject are shown in [Table 3](#pone.0208018.t003){ref-type="table"}.

10.1371/journal.pone.0208018.t002

###### The abundance of mycobacterial species discovered by sequencing.

![](pone.0208018.t002){#pone.0208018.t002g}

  Species                               Mean proportion reads per sample   No. subjects where present   No. subjects where most abundant   Number of OTUs
  ------------------------------------- ---------------------------------- ---------------------------- ---------------------------------- ----------------
  *M*. *avium*                          35.01%                             33                           14                                 107
  *M*. *abscessus* subsp. *bolletii*    17.44%                             28                           8                                  28
  *M*. *simiae*                         13.67%                             27                           8                                  15
  *M*. *abscessus* subsp. *abscessus*   6.55%                              23                           3                                  35
  *M*. *xenopi*                         5.32%                              13                           2                                  12
  *M*. *intracellulare chimaera*        4.40%                              22                           3                                  3
  *M*. *intracellulare*                 4.16%                              25                           1                                  37
  *M*. *kansasii*                       3.81%                              16                           2                                  5
  *M*. *arupense*                       1.37%                              13                           0                                  11
  *M*. *chelonae*                       1.08%                              13                           1                                  9
  *M*. *rhodesiae*                      0.99%                              9                            0                                  8
  *M*. *fortuitum*                      0.97%                              11                           0                                  13
  *M*. *gordonae*                       0.94%                              7                            0                                  4
  *M*. *psychrotolerans*                0.89%                              13                           0                                  4
  *M*. *malmoense*                      0.71%                              13                           0                                  13
  *M*. *peregrinum*                     0.58%                              9                            0                                  7
  *M*. *tuberculosis* complex           0.58%                              11                           0                                  20
  *M*. *neoaurum*                       0.52%                              3                            0                                  1
  *M*. *szulgai*                        0.39%                              13                           0                                  4
  *M*. *kubicae*                        0.02%                              2                            0                                  1
  *M*. *abscessus* complex              0.01%                              1                            0                                  1
  Unidentified                          0.58%                              10                           0                                  17

10.1371/journal.pone.0208018.t003

###### Sequencing and culture results for each subject.
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  ID    Group     Diagnosed species                                    No. mycobacterial sequences   No. mycobacterial OTUs   Most abundant species by sequencing   Cultured species   Cultured species detected by sequencing
  ----- --------- ---------------------------------------------------- ----------------------------- ------------------------ ------------------------------------- ------------------ -----------------------------------------
  282   Case      *M*. *abscessus*                                     156074                        57                       *M*. *abscessus subsp*. *bolletii*    *M*. *abscessus*   Yes
  272   Case      MAC                                                  75301                         173                      *M*. *avium*                          MAC                Yes
  238   Case      MAC                                                  11622                         119                      *M*. *avium*                          MAC                Yes
  212   Case      *M*. *abscessus*                                     4092                          74                       *M*. *abscessus subsp*. *abscessus*   *M*. *abscessus*   Yes
  216   Case      *M*. *abscessus*                                     3745                          39                       *M*. *abscessus subsp*. *abscessus*   MAC                Yes
  291   Case      *M*. *simiae*[\*](#t003fn002){ref-type="table-fn"}   1648                          55                       *M*. *simiae*                         No sample          \-
  248   Case      *M*. *fortuitum*                                     1410                          21                       *M*. *xenopi*                         No growth          \-
  270   Case      MAC                                                  557                           23                       *M*. *avium*                          No growth          \-
  269   Case      MAC                                                  441                           25                       *M*. *avium*                          MAC                Yes
  218   Case      MAC                                                  310                           27                       *M*. *avium*                          MAC                Yes
  226   Case      *M*. *kansasii*                                      247                           10                       *M*. *avium*                          *M*. *kansasii*    Yes
  277   Case      *M*. *kansasii*                                      204                           15                       *M*. *kansasii*                       *M*. *kansasii*    Yes
  301   Case      MAC                                                  199                           15                       *M*. *simiae*                         No sample          \-
  237   Case      *M*. *malmoense*                                     165                           3                        *M*. *simiae*                         *M*. *xenopi*      No
  205   Case      MAC                                                  133                           26                       *M*. *abscessus subsp*. *bolletii*    No growth          \-
  268   Case      MAC                                                  119                           30                       *M*. *intracellulare chimaera*        MAC                Yes
  271   Case      *M*. *kansasii*                                      102                           6                        *M*. *kansasii*                       M. kansasii        Yes
  229   Case      MAC                                                  101                           29                       *M*. *simiae*                         MAC                Yes
  249   Case      *M*. *kansasii*                                      97                            11                       *M*. *simiae*                         *M*. *kansasii*    No
  266   Case      *M*. *kansasii*                                      67                            5                        *M*. *abscessus subsp*. *abscessus*   *M*. *kansasii*    Yes
  294   Case      *M*. *abscessus*                                     57                            9                        *M*. *avium*                          No growth          \-
  214   Case      MAC                                                  54                            4                        *M*. *xenopi*                         *M*. *xenopi*      Yes
  276   Case      *M*. *xenopi*                                        47                            2                        *M*. *abscessus subsp*. *bolletii*    *M*. *xenopi*      No
  250   Case      MAC                                                  32                            3                        *M*. *abscessus subsp*. *bolletii*    No growth          \-
  245   Case      MAC                                                  17                            9                        *M*. *avium*                          MAC                Yes
  235   Case      MAC                                                  9                             6                        *M*. *intracellulare chimaera*        No growth          \-
  241   Case      MAC                                                  9                             5                        *M*. *intracellulare chimaera*        MAC                Yes
  299   Case      MAC                                                  7                             3                        *M*. *avium*                          No growth          \-
  224   Case      MAC                                                  6                             2                        *M*. *abscessus subsp*. *bolletii*    No growth          \-
  263   Case      MAC                                                  2                             1                        *M*. *avium*                          MAC                Yes
  222   Case      MAC                                                  1                             1                        *M*. *avium*                          *M*. *abscessus*   No
  303   Control                                                        468                           15                       *M*. *abscessus subsp*. *bolletii*    No growth          \-
  220   Control                                                        209                           50                       *M*. *abscessus subsp*. *bolletii*    No growth          \-
  306   Control                                                        176                           47                       *M*. *simiae*                         No growth          \-
  217   Control                                                        167                           22                       *M*. *avium*                          No growth          \-
  231   Control                                                        143                           12                       *M*. *simiae*                         No growth          \-
  210   Control                                                        140                           15                       *M*. *avium*                          No growth          \-
  302   Control                                                        111                           38                       *M*. *abscessus subsp*. *bolletii*    No growth          \-
  211   Control                                                        68                            9                        *M*. *simiae*                         No growth          \-
  305   Control                                                        31                            7                        *M*. *avium*                          No growth          \-
  225   Control                                                        26                            12                       *M*. *intracellulare*                 No growth          \-
  304   Control                                                        7                             6                        *M*. *chelonae*                       No growth          \-

Diagnosed species refers to the species isolated in culture leading to the original diagnosis of pulmonary NTM disease. Cultured species refers to the NTM species isolated from the study sample at the time of sequencing. ID = sample identifier.

\* isolated MAC prior to *M*. *simiae* but not re-isolated for 10 years

To allow comparison at the community level between subjects with varying depth of sequencing, samples were rarefied to a depth of 100 sequences leaving 25 subjects (18 cases and 7 controls) for analysis. The community structure of each subject is shown in [Fig 1](#pone.0208018.g001){ref-type="fig"}. After rarefaction the majority of subjects (92%) had more than one species present (median 5, range 2 to 17). There were no significant differences in the abundance of any NTM species between cases and controls, and no difference in community structure by PERMANOVA.

![Mycobacterial community structure in samples with more than 100 mycobacterial sequences.\
X-axis = samples, Y-axis = relative abundance, colours = species, left panel = cases, right panel = controls.](pone.0208018.g001){#pone.0208018.g001}

Exploration of diversity ([S5](#pone.0208018.s010){ref-type="supplementary-material"}, [S6](#pone.0208018.s011){ref-type="supplementary-material"} and [S7](#pone.0208018.s012){ref-type="supplementary-material"} Figs) revealed a significant reduction in diversity as measured by Shannon and Pielou's indices in NTM cases compared to controls. Within NTM cases alone, Shannon index and observed richness were higher in those receiving treatment for NTM, and Shannon and Pielou's indices were positively correlated with forced expiratory volume in 1 second.

Comparison with sputum culture {#sec006}
------------------------------

The cultured NTM species was detected by sequencing in 17 (81%) of the 21 culture positive samples ([Table 3](#pone.0208018.t003){ref-type="table"}). NTM were detected by sequencing in all of the 19 culture-negative samples. The median proportion of mycobacterial sequences was lower in the four discordant samples where the isolated species was not detected by sequencing (0.006%) compared to the concordant samples where the isolated species was also detected by sequencing (0.12%) or the culture negative samples (0.31%), although this difference did not reach significance ([S8 Fig](#pone.0208018.s013){ref-type="supplementary-material"}, Kruskal-Wallis *P* = 0.054).

In 13 of the 21 cases (62%) with culture-positive sputum the isolated species was also the most abundant species found by sequencing. Agreement was highest for *M*. *kansasii*, which was the most abundant species in both culture positive subjects, and lowest for *M*. *simiae*, which was not cultured from any of the five subjects in which it was the most abundant species by sequencing. No sputum sample isolated more than one NTM species by culture. However, in 12 cases (39%) more than one NTM species had been previously isolated at the time of study enrolment ([S4 Table](#pone.0208018.s005){ref-type="supplementary-material"}).

Discussion {#sec007}
==========

This study has demonstrated the utility of next generation sequencing with multiplexed barcoded paired-end primers to sequence mycobacterial hsp65 directly from sputum samples. The majority of sequences were identified to the species level. The study is the first to provide a profile of mycobacterial communities within the lung.

The use of a mock community confirms the ability to detect a broad range of NTM species and allows assessment of amplification bias. Contamination is an important concern in microbiome studies \[[@pone.0208018.ref021]\] and the use of extraction controls mirroring the processing of sputum samples provides reassurance that the findings are unlikely to be the result of contamination.

Mycobacterial sequences were recovered from every sample in both cases and controls, regardless of their growth in culture or the presence of clinical disease. It has long been appreciated that mycobacteria may be cultured from subjects in the absence of disease. This has led to the development of microbiological criteria for the diagnosis of NTM disease \[[@pone.0208018.ref010]\] which are not met by around half of subjects in whom NTM are isolated \[[@pone.0208018.ref022],[@pone.0208018.ref023]\]. This has been attributed to contamination or 'casual' isolation of transiently inhaled organisms, however the data from this present study suggest that this isolation may reflect the true recovery of NTM from the respiratory tract, and that sputum culture may in fact lack sensitivity to the presence of NTM. However, the detection of microbial DNA by sequencing does not necessarily indicate the presence of viable organisms and it is also possible that the recovery of some sequences, particularly those from species not known to cause disease, may originate from non-viable inhaled organisms. The control group was composed of subjects with bronchiectasis, a known risk factor for NTM disease, and it may be that the ubiquitous finding of NTM is restricted to this particular clinical phenotype. A useful avenue for further work will be to determine if NTM are present in the lungs of subjects with other chronic lung diseases, or even in healthy individuals.

Despite their ubiquity in the environment, mycobacteria have not been frequently reported in previous studies of the lung microbiome. Their abundance may however be underestimated for a variety of reasons. In contrast to many other taxa most mycobacteria possess only a single copy of the 16S rRNA gene \[[@pone.0208018.ref024]\], their protective cell wall is particularly resistant to lysis for DNA extraction \[[@pone.0208018.ref025]\] and a number of primers targeting the 16S rRNA gene do not comprehensively cover the genus \[[@pone.0208018.ref026]\].

Several culture-based studies have found that the isolation of more than one NTM species from the same individual is not uncommon \[[@pone.0208018.ref004],[@pone.0208018.ref005],[@pone.0208018.ref022]\] and another key finding of this study is that in nearly all samples mycobacteria were present as a community rather than a single species. This was not detected by sputum culture which failed to detect more than one species in any individual, although the historic isolation of more than one species was seen in over one-third of cases. This is important finding especially as the current paradigm of NTM infection is that of infection with a single species, which along with the radiological pattern of disease defines that individual's diagnosis and governs their treatment.

There was a tendency for one NTM species to dominate the community and this was more marked in NTM cases. Although not statistically significant, cases had lower alpha diversity indices than controls. Diversity indices were also lower in cases with poor lung function but higher in those treated for NTM. This may represent the expansion of one pathogenic species in subjects who develop clinical NTM disease. The differences however were small and dominance by a single species was still frequently seen in controls without disease. In four samples the cultured NTM species was not detected by sequencing; this is highly likely to be due to the very low numbers of mycobacterial sequences (between 1 and 165) recovered from these samples.

The most abundant mycobacteria species sequenced was *M*. *avium*, in keeping with the results of conventional culture in the study cohort and other published culture-based studies \[[@pone.0208018.ref023],[@pone.0208018.ref027]--[@pone.0208018.ref029]\]. Surprisingly the second most common species was *M*. *simiae*, despite not being detected by culture in any sample and not being a commonly encountered species in the UK or the rest of Europe. The reason for this finding is unclear. There was no clear bias seen in favour of *M*. *simiae* amplification in the mock community and the bacterium is readily isolated by conventional culture techniques with no special requirements.

Measures of mycobacterial diversity were lower in NTM cases compared to controls, and within NTM cases higher diversity was associated with better lung function and with treatment directed against NTM. These findings parallel those seen in studies of the bacterial microbiome in respiratory disease which have repeatedly found lower bacterial diversity to be associated with more severe disease \[[@pone.0208018.ref030]--[@pone.0208018.ref036]\].

The only comparable culture independent study employing human clinical samples was reported by Macovei and colleagues \[[@pone.0208018.ref009]\] who used a nested PCR targeting mycobacteria to perform partial sequencing of the 16S rRNA gene on samples from the oral cavity and upper respiratory tract of healthy subjects. In keeping with the present study multiple taxa of NTM were found to be present in every subject.

The principal limitation of the present study is the recovery of a large amount of non-mycobacterial sequences, which had the effect of significantly reducing the depth of mycobacterial sequencing. Consequently the data may underestimate the true diversity of mycobacteria present, and may fail to detect mycobacteria in some samples with low sequencing depth. The amplification of non-mycobacterial sequences also meant that the primers could not be used for quantitative PCR to estimate the absolute abundance of mycobacteria in the samples. The mock community data also suggests that there is some variation in amplification between species which may influence estimates of community structure.

Sputum samples are subject to oral contamination and may originate from anywhere within the lung, and so potentially may not reflect the community composition at the site of localised disease. However bronchoscopy would not be feasible in many of the study participants who have advanced pulmonary disease and other comorbidities, and bronchoscopic sampling is also not without risk of contamination \[[@pone.0208018.ref037]\]. Given the known presence of NTM in the oral cavity \[[@pone.0208018.ref009]\] contamination is a potential source of NTM sequences in the sputum, however in comparison to sputum oral secretions are likely to have contributed only a small fraction of the total biomass sequenced, and reassuringly there was no relationship between amplicon concentration and mycobacterial abundance, which has been shown to be a marker of contamination in 16S data \[[@pone.0208018.ref038]\].

In the present study subjects were sampled at a single time point and only one sputum sample was used for sequencing. Future work will analyse successive sputum samples at a single time point to assess the reproducibility of the community structure, as well as longitudinal sampling to characterise the resilience and responsiveness of the community to changes in clinical state over time.

Finally, the study group was heterogeneous and composed of individuals with different pulmonary conditions receiving different treatments, including antibiotics and therapy for NTM. There are differences between NTM cases and the control group, notably the use of NTM therapy which was by definition absent in the control group, and a lack of subjects with COPD in the control group as sufficient sputum could not be obtained for sequencing in these subjects. These differences may confound analyses between groups. Furthermore, the small sample size means the analysis of diversity metrics is underpowered. Therefore these particular findings should be treated as exploratory.

Conclusions {#sec008}
===========

This study represents the first use of multiplexed next generation partial sequencing of the *hsp65* gene to characterise mycobacterial communities in the lung. This found that NTM were present in all study subjects regardless of their isolation by conventional culture or the presence of clinical NTM disease, and that multiple species of NTM were usually present in the same individual.
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Just as the advent of culture independent techniques has revealed the unprecedented diversity of the lung microbiome, and a new appreciation of the complex relationship between bacterial communities in the lung and clinical disease, these findings suggest that the relationship between NTM present in the lung and clinical disease may also be more complex than previously thought. Whilst requiring further validation in independent cohorts, our findings potentially have important implications for our understanding of the pathogenesis and also potentially the management of this challenging disease.
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